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Introduction
Human immunodeficiency virus (HIV) may be transmitted 
from an infected mother to her child during pregnancy, 
delivery or breastfeeding. Without any intervention, 
transmission rates may range from 15-45%. However, 
this can be reduced to < 5% with effective drug therapy.1 
A scheduled Caesarean section that is performed before 
the onset of labour or the rupture of membranes has been 
shown to reduce the intrapartum risk in a meta-analysis of 
earlier studies.2 
The most recent Cochrane review (2005) of the efficacy 
and the safety of Caesarean section in preventing the 
vertical transmission of HIV-1 concluded that Caesarean 
section that is performed before labour or the rupture of 
membranes was shown to be effective in earlier studies that 
were conducted among women who received zidovudine 
[(ZDV), formerly azidothymidine (AZT)] or no antiretroviral 
(ARV) therapy.3 The review further concluded that the benefit 
of performing an elective Caesarean section outweighed 
the risk of postpartum morbidity in HIV-infected women. 
However, balancing the risk to benefit ratio is influenced by 
the underlying rate of mother-to-child transmission (MTCT) 
in an individual patient. 
Caesarean section, while initially shown to reduce the MTCT 
risk, is itself associated with significant morbidity to the 
mother. This is the inherent risk of any surgical procedure, 
compounded by the HIV-related immunosuppression which 
predisposes the woman to postpartum infectious morbidity. 
The latter occurs despite the routine use of prophylactic 
antibiotics that are given during the procedure. Pregnancy-
related sepsis is among the leading causes of maternal 
deaths,4 particularly in women who deliver by Caesarean 
section.5 Several authors have reported an increase in 
the risk of postpartum endometritis and other infectious 
morbidity in HIV-infected women undergoing Caesarean 
section, compared to those who are uninfected.6-8 
The conclusions of Read and Newell in the Cochrane review 
(2005) are worth noting, namely that the risk of vertical 
transmission among women with less advanced or well 
controlled disease is very low, and hence the benefit of a 
Caesarean section is unclear. It may well be that the primary 
objective of preventing MTCT by performing an elective 
Caesarean section is outweighed by the morbidity that may 
be experienced by the mother, particularly because less 
invasive interventions are not only very effective, but also 
more feasible to implement in resource-poor countries.
Antiretroviral use renders Caesarean 
section a less attractive intervention in 
reducing mother-to-child transmission 
Significant strides have been made with regard to pursuing 
interventions that reduce antepartum and postpartum HIV 
transmission. In the antenatal period, the use of ARVs of 
different combinations has been found to be effective.9-11 
Whereas single-dose nevirapine (NVP), administered during 
labour, was considered to be the minimum that resource-
poor countries could offer to many women,12 there is now 
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sufficient evidence of the efficacy of longer courses of ARVs 
dispensed during pregnancy in resource-poor countries.13 
ZDV, administered twice daily from as early as 14 weeks, is 
now recommended by the World Health Organization (WHO) 
in resource-poor countries and has been shown to be more 
effective than starting the same prophylaxis at 36 weeks.14 
The addition of single-dose NVP has further enhanced this 
efficacy.15. 
Implementation of this recommended combination has 
resulted in the transmission rates in the South African 
prevention of mother-to-child transmission (PMTCT) 
programme being reduced to < 4%.13 To cover for possible 
resistant mutations that may arise from the use of single-
dose NVP, a “tail cover”, consisting of either Truvada® 
(emticitrabine plus tenofivir), or alternatively ZDV plus 
lamuvidine (3TC), is added to the mother’s therapy in the 
immediate peripartum period.16,17
Furthermore, progress has also been made with efforts 
to reduce postnatal transmission through breastfeeding. 
Unlike the case in resource-rich countries, where the risk 
of breastfeeding can be avoided by alternative feeding 
methods, e.g. infant formula, this practice has shown to 
have deleterious results in resource-poor countries..A 
study in Botswana demonstrated that infant survival was 
compromised in those who were formula-fed (while trying 
to avoid transmission from breast milk).18 The use of 
either ARVs, administered to the mother [as highly active 
antiretroviral therapy (HAART)], or infants, has been shown 
to significantly reduce the risk of postnatal transmission19 
and to improve infant survival. In the postpartum period, 
infants should receive at least six weeks of ARV post-
exposure prophylaxis, or for the duration of breastfeeding, 
until a week postcessation.18,20,21 Studies have shown that 
this is as effective as maternal HAART if the mother is 
breastfeeding.18 This practice is now recommended for up 
to12 months.22
Based on strong evidence that has emerged from 
different settings in resource-poor countries, the place 
of an elective Caesarean section performed for the sole 
purpose of reducing MTCT is now being questioned. This 
has necessitated a reappraisal of the issue of scheduled 
Caesarean section to prevent MTCT.
Is there any evidence that scheduled 
Caesarean section reduces mother-to-
child transmission in patients receiving 
highly active antiretroviral therapy?
Since the Cochrane review, the efficacy of scheduled 
Caesarean section in the presence of undetectable viral 
load (VL), either consequent to HAART use, or long-term 
use of ARV prophylaxis started early in pregnancy, has been 
re-examined.23,24 The findings of some key studies that have 
attempted to address this question are summarised.
The authors of the European Collaborative Study23 examined 
MTCT rates in the HAART era. They also investigated 
the effects of elective Caesarean section, the duration of 
ruptured membranes and prematurity. Of the 4 525 mother-
infant pairs who were enrolled in the study between 1998 
and 2004, 44% of these were in the HAART era (1 983 
pairs). In the majority of cases (57.8% or 1 147), HAART was 
initiated during pregnancy. In this study, in which 61% of the 
cohort delivered by elective Caesarean section, the mode of 
delivery was associated with vertical transmission. Infection 
occurred in 6.5% of infants who were delivered vaginally 
and in 1.65% of those who delivered by elective Caesarean 
section. This benefit of reduced vertical transmission was 
noticed, even after controlling for VL. The latter was found 
to be “the pre-eminent independent risk factor”. VL > 1 000 
copies/ml was associated with a 12-fold increase in the risk 
of MTCT. However, even after controlling for VL, elective 
Caesarean section remained significantly associated with a 
reduced risk of MTCT, a benefit that persisted even in a group 
of women with undetectable VL who had been receiving 
antenatal HAART. The study found that elective Caesarean 
section delivery was associated with an approximate 40% 
reduction in the risk of vertical HIV transmission, compared 
with vaginal delivery. However, the difference was not 
statistically significant. In the same study, the authors found 
that prematurity and duration of rupture of membranes were 
also associated with an increased risk of MTCT. 
In summary, the study showed that elective Caesarean 
section significantly reduced MTCT in the whole group, i.e. 
pre-HAART and during the HAART era, even in those with 
undetectable VL using HAART. However, the study was 
not powered to further adjust for the use of HAART. The 
authors concluded that a large study was needed to resolve 
this issue, one that would require approximately 6 345 and 
7 217 mother-child pairs from vaginal and Caesarean section 
deliveries, respectively, with 90% power.23,25 Evidence 
seems to suggest that a large number of Caesarean section 
need to be performed to prevent a single case of MTCT. 
In another study, Warszawski et al aimed to determine 
the rate of MTCT according to various components of 
prophylaxis.26 Overall, there were 5 271 eligible mother-
child pairs over a period of seven years, 19% of whom 
received monotherapy, 33% dual-drug therapy and 48% 
HAART at delivery. There were 67 infected neonates (an 
overall MTCT rate of 1.3%), and the risk was significantly 
associated with prematurity, HIV-1 RNA level, cluster of 
differentiation 4 cell count and duration of ART during the 
pregnancy. The study found that MTCT rates were not 
influenced by the mode of delivery. The only factor that 
influenced transmission was intrapartum prophylaxis, both 
in those with or without virological suppression. In general, 
for term deliveries where the mother had VL < 400 copies/
ml, the only factor that was found to be associated with 
transmission was the duration of antenatal therapy [with 
the odds ratio (OR) calculated per week as 0.94, 95% 
confidence interval (CI): 0.90-0.99, p-value = 0.03]. In 
other words, each week of ARV use reduced the risk of 
transmission by 6%. There was a sharp reduction in MTCT 
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after the first 12 weeks of ARV use and the duration of ART 
remained significantly associated with MTCT, even after 
adjustments. The median duration of ART during pregnancy 
was significantly shorter in mothers who transmitted the 
virus to the infant (9.5 weeks), compared to those who did 
not (16 weeks, p-value < 0.001). Among term births with 
failure of virological suppression, defined as VL > 50 copies/
ml, intrapartum prophylaxis that was given intrapartum 
was strongly associated with a lower risk of transmission 
(5.3% compared to 22.7% without intrapartum prophylaxis, 
p-value = 0.009). The OR for MTCT, when no intrapartum 
therapy was given, was calculated as 4.72 (95% CI: 1.42-
15.71). In summary, the study found that the duration of 
ARV during pregnancy was the most important determining 
factor in the risk of vertical HIV transmission, and if VL was 
not suppressed, then intrapartum prophylaxis reduced 
the risk.
In the AmRo study, investigators reported on 143 HIV-
infected women who received HAART, 78% of whom 
attempted vaginal delivery (111/143).24 These had a median 
VL of < 50 copies/ml (undetectable in 85%). Vaginal delivery 
was successful in 62% of cases, with no cases of MTCT 
(95% CI: 0-2.4%). It was believed that when HAART was 
started before the third trimester, it was able to suppress 
the HIV RNA level to < 50 copies/ml, and thus allow for safe 
vaginal delivery. It was suggested that, in this scenario, at 
least 131 instances of elective Caesarean section would 
need to be carried out to prevent a single case of MTCT 
from occurring. The study, like others,27 also found an 
association between the use of HAART in the first trimester 
and the risk of preterm delivery. 
It seems that there is mounting evidence that HAART use 
may eliminate the need for elective Caesarean section 
to prevent MTCT, provided there is sufficient time before 
delivery. In a national surveillance study in the UK, Townsend 
et al found that the “MTCT rate was 1.2% overall, (61/5 
151,95% CI: 0.9-1.5%) and 0.8% for women who received 
at least 14 days of ART (40/4 864, 95% CI:0,6 - 1,1%)”.28 In 
a local study in South Africa, women who became pregnant 
on HAART had lower MTCT rates compared to those who 
initiated HAART during pregnancy (0.7% vs. 5.7%, p-value 
= 0.01).29 In the latter group, there was 8% reduction in the 
odds of transmission for each additional week of treatment 
(95% CI: 0.87-0.99, p-value = 0.02). Overall, the MTCT rate 
was 4.9% (43 of 874), and none of the different HAART 
regimens were superior to the others. Despite all these 
interventions, there is “residual transmission”, as termed 
by Tubiana et al, in which MTCT continues to occur in the 
context of full-term deliveries and a maternal viral load of 
< 400 copies/ml, in the absence of breastfeeding.30 In a 
study in which cases of vertical transmission were matched 
with controls in which there was no transmission, “the only 
factor that remained independently associated with residual 
transmission of HIV-1 was early control of the plasma HIV-1 
RNA level”. In this study, the majority of patients delivered 
by Caesarean section. Caesarean section was not found to 
influence the rates of MTCT.
Summary of evidence
Evidence from the above studies can be summarised as 
follows:
•	 Vaginal delivery seems to be safe among women on 
HAART with virological suppression.
•	 The duration of ARV use during pregnancy (preferably 
HAART) greatly determines virological success, and 
consequently the risk of MTCT.
•	 Each week of triple ARV therapy reduces the odds ratio 
of transmission by 6-8%.25,29
•	 In the absence of virological suppression, intrapartum 
prophylaxis significantly reduces the risk of MTCT.
•	 While there might still be a benefit in performing 
Caesarean section in women on HAART, the number 
that is needed to treat is large (> 100 Caesarean sections 
need to be performed to prevent one case of MTCT from 
occurring).
The multipronged strategy of early initiation of ARV therapy 
during pregnancy, administration of ARV during labour and 
delivery, as well as pre-exposure prophylaxis to the infant 
in the postpartum period, has proven to be very effective 
in reducing vertical transmission to < 4% in resource-poor 
countries.13 The latest evidence suggests that the earlier 
that ARV drugs are started during pregnancy, the more 
effective the efforts to prevent in utero and intrapartum 
transmission. However, studies cannot determine “the 
optimal gestational age at which ART should be started, 
the optimal gestational age at which viral load should be 
controlled, or the threshold of viral load to be reached”,30 in 
order to completely eliminate the risk of MTCT.
Practice points
Scenario A: Assuming a woman attended for care early in 
pregnancy, and that the HIV infection has been diagnosed 
for the first time, in cases where resources are not a 
prohibiting factor:
•	 Carry out a baseline clinical (WHO) staging, viral load and 
CD 4 count.
•	 If the CD4 count is < 350, initiate HAART for maternal 
health, which will also benefit the infant. HAART will need 
to be continued for life.
•	 If the CD4 count is > 350, give HAART to prevent MTCT 
(similar to Scenario B).
•	 Where feasible, repeat VL count at > 36 weeks in order to 
decide on the mode of delivery.
•	 If VL > 1 000 cp/ml, a woman should be counselled on 
the risk of MTCT, which could be obviated by performing 
a scheduled Caesarean section. 
•	 In this instance, intrapartum prophylaxis is imperative, 
whether or not the patient undergoes a scheduled 
Caesarean section (ZDV 300 mg given three hours 
before Caesarean section), and particularly if she opts 
for vaginal delivery. 
•	 If the VL is undetectable, vaginal delivery is considered 
to be safe with intrapartum prophylaxis.
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•	 Patients should be counselled that the absolute 
elimination of risk of MTCT is not guaranteed.
Scenario B: In cases where resources are constrained, it 
may not be possible to offer HAART for the sole purpose 
of preventing MTCT, performing a routine VL count close to 
term or scheduling a Caesarean section for PMTCT.
Therefore:
•	 HAART should be offered as early as possible in the 
second trimester to women whose CD4 count is < 350, 
or to those who are WHO stages III or IV clinically.
•	 For women with a CD4 count > 350, ZDV 300 mg should 
be started twice daily as early as 14 weeks. The dose 
should be increased to 300 mg three hourly during 
labour, with the addition of a single dose of NVP during 
labour. 
•	 A “tail cover” consisting of either Truvada® or ZDV plus 
3TC should be given to the mother.
•	 In all instances, the infant should receive a six-week 
course of ARV therapy (either ZDV or NVP). If the mother 
has chosen to breastfeed, this should continue for up 
to 12 months and should preferably be exclusive for 
the initial period. Maternal HAART or infant prophylaxis 
should be given for the duration of the breastfeeding 
period. The latter is preferred as it preserves treatment 
options for the mother (if she does not require HAART 
for her health).
Conclusion
In conclusion, evidence shows that in the era of highly 
effective ARV combinations that are used for PMTCT, 
including HAART for the mother, the role of a scheduled 
Caesarean section to prevent MTCT seems to be limited 
and remains questionable. However, it is concerning to note 
that while a scheduled Caesarean section is not always 
necessary, many procedures continue to be performed 
through fear of the unknown on the part of the practitioner 
and the “adequately counselled” mother (possibly what 
Tubiana et al termed “residual transmission”).30 While the 
private sector may be able to carry the increased number 
of Caesarean sections that are carried out for PMTCT, this 
practice would be difficult to implement on a wider public 
health scale, given the high costs of Caesarean section and 
the implications for infrastructure and personnel.
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